Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration
- PMID: 15468611
- DOI: 10.3949/ccjm.71.suppl_3.s8
Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration
Abstract
The main treatment goal in patients with chronic hepatitis C virus (HCV) infection is the prevention of progressive hepatic fibrosis by eradicating serum and intrahepatic virus. The current standard of care in previously untreated patients with chronic hepatitis C is combination therapy with pegylated interferon alfa and ribavirin. The duration of therapy and the dose of ribavirin should be determined according to the patient's HCV genotype. Adherence to the full dose of therapy for the prescribed treatment duration enhances the likelihood of sustained virologic response. Early virologic response is a good predictor of eventual sustained response for patients with HCV genotype 1 infection. Despite important gains in treating chronic hepatitis C, many treatment challenges remain.
Similar articles
-
[Retreatment options for patients with chronic hepatitis C].Acta Med Croatica. 2009 Dec;63(5):417-22. Acta Med Croatica. 2009. PMID: 20198901 Croatian.
-
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.Gastroenterology. 2006 Oct;131(4):1040-8. doi: 10.1053/j.gastro.2006.07.022. Epub 2006 Jul 24. Gastroenterology. 2006. PMID: 17030174 Clinical Trial.
-
Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection.Clin Gastroenterol Hepatol. 2010 Oct;8(10):884-90. doi: 10.1016/j.cgh.2010.06.019. Epub 2010 Jun 30. Clin Gastroenterol Hepatol. 2010. PMID: 20601130
-
The evolving treatment of chronic hepatitis C: where we stand a decade out.Cleve Clin J Med. 2004 May;71 Suppl 3:S3-7. doi: 10.3949/ccjm.71.suppl_3.s3. Cleve Clin J Med. 2004. PMID: 15468610 Review.
-
[Treatment of hepatitis C virus infection].Praxis (Bern 1994). 2005 May 4;94(18):721-6. doi: 10.1024/0369-8394.94.18.721. Praxis (Bern 1994). 2005. PMID: 15938383 Review. German.
Cited by
-
Treatment outcomes in a centralized specialty clinic for hepatitis C virus are comparable with those from clinical trials.Can J Gastroenterol. 2006 Feb;20(2):87-90. doi: 10.1155/2006/148962. Can J Gastroenterol. 2006. PMID: 16482233 Free PMC article.
-
Translational research of telecare for the treatment of hepatitis C.Biomed Res Int. 2014;2014:195097. doi: 10.1155/2014/195097. Epub 2014 Jun 10. Biomed Res Int. 2014. PMID: 25013762 Free PMC article.
-
Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion.J Virol. 2008 Mar;82(5):2120-9. doi: 10.1128/JVI.02053-07. Epub 2007 Dec 12. J Virol. 2008. PMID: 18077707 Free PMC article.
-
Hepatitis C virus-host interactions, replication, and viral assembly.Curr Opin Virol. 2012 Dec;2(6):725-32. doi: 10.1016/j.coviro.2012.09.013. Epub 2012 Oct 18. Curr Opin Virol. 2012. PMID: 23083892 Free PMC article. Review.
-
The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors.Protein Sci. 2014 Jun;23(6):723-34. doi: 10.1002/pro.2456. Epub 2014 Apr 5. Protein Sci. 2014. PMID: 24639329 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
